In Vivo is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
BMS, Merck develop muraglitazar for diabetes: terminated
23 Feb 2006
Bristol-Myers Squibb and Merck & Co. will jointly develop and commercialize Bristol's muraglitazar, a dual peroxisome proliferator-activated receptor (PPAR) agonist that is in Phase III clinical trials to manage Type II diabetes and the lipid abnormalities often associated with the disease, especially high triglyceride and low HDL levels.
R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?